-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Benzinga·08/12/2026 15:16:24
Listen to the news
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.